Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: Results from a retrospective multi-center European study

European Journal of Cancer

Volumn 56, Issue , 2016, Pages 59-68

  Markar, Sheraz R ^a   Gronnier, Caroline ^b,c,d   Pasquer, Arnaud ^e   Duhamel, Alain ^b,c,f   Beal, Hélène ^b,c,f   Théreaux, Jérémie ^g   Gagnière, Johan ^h   Lebreton, Gil ⁱ   Brigand, Cécile ^j   Meunier, Bernard ^k   Collet, Denis ^l   Mariette, Christophe ^b,c,d,f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f SIRIC OncoLille ^*  (France)

^g BREST UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ CHU CÔTE DE NACRE   (France)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^l HAUT LÉVÊQUE HOSPITAL   (France)

more..

Author keywords

cT2N0M0; Neoadjuvant treatment; Oesophageal cancer; Review; Surgery; Survival

Indexed keywords

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; EUROPE; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; EUROPE; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84955439090     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.024     Document Type: Article

References (21)

1. C. Mariette, G. Piessen, N. Briez, and et al. Oesophago-gastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 12 2011 296 305
2. P. Van Hagen, M.C. Hulshof, J.J. van Lanschot, and et al. Preoperative chemoradiotherapy for esophageal or junctional cancer N Engl J Med 366 2012 2074 2084
3. K.M. Sjoquist, B.H. Burmeister, B.M. Smithers, and et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis Lancet Oncol 12 2011 681 692
4. C. Mariette, L. Dahan, F. Mornex, and et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD9901 J Clin Oncol 32 2014 2416 2422
5. W.H. Chen, Y.K. Chao, H.K. Chang, and et al. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma Dis Esophagus 25 2012 250 255
6. P.J. Speicher, A.M. Ganapathi, B.R. Englum, and et al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer J Thorac Oncol 9 2014 1195 1201
7. B.M. Stiles, F. Mirza, A. Coppolino, and et al. Clinical T2-T2N0MO esophageal cancer: the risk of node positive disease Ann Thorac Surg 92 2011 491 496
8. J.Q. Zhang, C.M. Hooker, M.V. Brock, and et al. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2N0 esophageal cancer patients due to inaccurate preoperative staging Ann Thorac Surg 93 2012 429 437
9. J.P. Dolan, B.S. Diggs, R.A. Luna, and et al. Significant understaging is seen in clinically stage T2N0 esophageal cancer patients undergoing esophagectomy Dis Esophagus 2015 [Epub ahead of print]
10. T.W. Rice, D.P. Mason, S.C. Murthy, and et al. T2N0M0 esophageal cancer J Thorac Cardiovasc Surg 133 2007 317 324
11. E.J. Bergeron, J. Lin, A.C. Change, and et al. Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies J Thorac Cardiovasc Surg 147 2014 765 771
12. T.D. Crabtree, A.S. Kosinski, V. Puri, and et al. Evaluation of the reliability of clinical staging of T2N0 esophageal cancer: a review of the Society of Thoracic Surgeons database Ann Thorac Surg 93 2013 382 390
13. N. Safieddine, W. Xu, S.M. Quadri, and et al. Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention J Thorac Cardiovasc Surg 137 2009 36 42
14. W.B. Robb, M. Messager, D. Goere, and et al. Predictive factors of postoperative mortality after junctional and gastric adenocarcinoma resection JAMA Surg 148 2013 624 631
15. J.T. Martin, M. Worni, J.B. Zwischenberger, and et al. The role of radiation therapy in resected T2N0 esophageal cancer: a population-based analysis Ann Thorac Surg 95 2013 453 458
16. S. Markar, C. Gronnier, A. Duhamel, and et al. Pattern of postoperative mortality after esophageal cancer resection according to center volume: results from a large European multicenter study Ann Surg Oncol 22 2015 2615 2623
17. th, 2015.
18. N. Briez, G. Piessen, F. Bonnetain, and et al. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicenter randomised controlled phase III trial - the MIRO trial BMC 11 2011 310
19. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
20. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM classification of malignant tumours (7th ed.). John Wiley & Sons, 2009.
21. D.K. Dhar, M. Tachibana, N. Kinukawa, and et al. The prognostic significance of lymph node size in patients with squamous esophageal cancer Ann Surg Oncol 9 2002 1010 1016